Immunological approaches to the breakdown of hepatitis B viral persistence

Chinese Medical Journal

Volumn 111, Issue 6, 1998, Pages 560-564

  Lau, George K K ^a   Wang, Bao'en ^b   Carman, William ^c  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DNA VACCINE; EPITOPE; FAMCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; LAMIVUDINE; NUCLEOSIDE ANALOG; THYMOSIN ALPHA1; THYMOSIN FRACTION 5;

ADOPTIVE TRANSFER; ANTIGEN ANTIBODY COMPLEX; BONE MARROW TRANSPLANTATION; CLEARANCE; CLINICAL TRIAL; DRUG EFFICACY; HEPATITIS B; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INTRAMUSCULAR DRUG ADMINISTRATION; NONHUMAN; PERSISTENT INFECTION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; THYMOSIN;

EID: 0031809516     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Lau GKK, Wu PC, Lai CL. Natural history of chronic HBV infection. HK Med J 1997(in press).
2. Lok ASF. Treatment of chronic hepatitis B. J Viral Hepatitis 1994; 1: 105.
3. Mutchnick MG, Appleman HD, Chung HT, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology 1991; 14: 409.
4. Dienstag JL, Perrillo RP, Schiff EF, et al. A preliminary trial of lamuvidine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657.
5. Main J, Brown JL, Karayiannis P, et al. A double blind, placebo-controlled study to assess the effect of famciclovir on viral replcation in patients with chronic hepatitis B virus infection. J Hepatol 1994; 21(Suppl 1):S32.
6. Rehermann B, Pasquinelli C, Mosier SM, et al. Chisari FV. HBV sequence variation in CTL epitopes is not common in patients with chronic hepatitis B virus infection. J Clin Invest 1995; 96: 1527.
7. Eckhardt SG, Milich DR, McLachlan A, et al. Hepatitis B virus core antigen has two nuclear localization sequences in the argininerich carboxyl terminus. J Virol 1991; 65: 575.
8. Nassal M. The arginine-rich domain of the hepatitis B virus core protein is required for pregenome encapsidation and productive viral positive-strand DNA synthesis but not for virus assembly. J Virol 1995; 69: 4107.
9. Eble BE, MacRae DR, Lingappa VR, et al. Multiple topogenic sequences determine the transmembrane orientation of hepatitis B surface antigen. Mol Cell Biol 1987; 7: 3591.
10. Rehermann B, Fowler P, Sidney J, et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995; 181: 1047.
11. Bamaba V, Franco A, Alberti A. Recognition of hepatitis B envelope proteins by liver-infiltrating T lymphocytes in chronic HBV infection. J Immunol 1989; 141: 2650.
12. Rehermann B, La D, Hoofnagle J, et al. Cytotoxic T lymphocte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 1996; 97: 1.
13. Lau GKK, Lok ASF, Liang RH, et al. Clearance of HBsAg after bone marrow transplantation: role of adoptive immunity transfer. Hepatology 1997; 25: 1497.
14. Beasley RP, Hwang L. Postnatal infectivity of hepatitis B surface antigen-carrier mothers. J Infect Dis 1983; 147: 185.
15. Ferrari C, Bertoletti A, Penna A, et al. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest 1991; 88: 214.
16. Rehermann B, Ferrari C, Pasquinelli C, et al. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nature Med 1996; 1104.
17. Chazouilleres O, Mamish D, Kim M, et al. "Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994; 343: 142.
18. Marshall GD, Thurman GB, Rossio JL, et al. In vivo generation of 19. Mutchnick MG, Prieto JA, Schaffner JA, Weller FE. Thymosin modulation of regulatory T-cell function. Clin Immunol Immunopathol 1982; 23: 626.
19. Sztein MB, Serrate SA, Goldstein AL. Modulation of intereukin 2 receptor expression on normal human lymphocytes by thymic hormones. Proc Natl Acad Sci U S A 1986; 83: 6107.
20. Mutchnick MG, Jaurequi JI, Shafritz. Sustained response to thymosin therapy in patients with chronic hepatitis. Hepatology 1992; 16: 66A.
21. Wen YM, Wu XH, Hu DC, et al. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet 1995; 345: 1575.
22. Pol S. Specific Vaccine therapy in chronic hepatitis B infection. Lancet 1994; 344: 342.
23. Celis E, Ou D, Otvos L Jr. Recognition of hepatitis B surface antigen by human T lymphocytes. Proliferation and cytotoxic responses to a major antigenic determinant defined by synthetic peptides. J Immunol 1988; 140: 1808.
24. Jin Y, Shih WK, Berkower I. Human T cell response to the surface antigen of hepatitis B virus (HBsAg). Endosomal and nonendosomal processing pathways are accessible to both endogenous and exogenous antigen. J Exp Med 1988; 168: 293.
25. Penna A, Fowler P, Bertoletti A, et al. Hepatitis B virus (HBV)-specific cytotoxic T-cell (CTL) response in humans: characterization of HLA class II -restricted CTLs that recognize endogenously synthesized HBV envelope antigens. J Virol 1992; 66: 1193.
26. Bertoletti A, Ferrari C, Fiaccadori F, et al. HLA class-I restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci USA 1991; 88: 10445.
27. Guilhot S, Fowler P, Portillo G, et al. Hepatitis B virus (HBV) specific cytolytic T cell response in human: production of target cells by stable expression of HBV-proteins in immortalized human B cell lines. J Virol 1992; 66: 2670.
28. Tsai SL, Chen MY, Lai MY, et al. Acute exacerbations of chronic thpe B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. J Clin Invest 1992; 89: 87.
29. Vitiello A, Ishioka G, Grey HM, et al. Developement of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. 1. Induction of a primary cytotoxic T lymphocyte response in human. J Clin Invest 1995; 95: 341.
30. Heathcote J, McHutchison K, Benner T, et al. CY-1899: A therapeutic vaccine for chronic hepatitis B. Hepatology 1996; 24: 283 A.
31. Shouval D, Ilan Y. Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer of immunity to hepatitis B virus. J Hepatol 1995; 23: 98.
32. Davis HL, Schirmberk R, Reimann J, et al. DNA-mediated immunization in mice induces a potent MHC class- I restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein. Hum Gene Ther 1995; 6: 1447.
33. Davis HL, McCluskie MJ, Gerin JL, et al. DNA vaccine for hepatitis B: Evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc Nat Acad Sci USA 1996; 93: 7213.